Careside to launch point-of-care analyser
This article was originally published in Clinica
US company Careside is on schedule for a year-end launch of a point-of-care blood analyser for a wide range of routine tests, now that it has gained FDA clearance for the device. The device is already cleared for professional laboratory use, but the new clearance opens the potential market to doctors' offices and health clinics. The company's shares increased 12.5% to $6.75 on the day of the news.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.